Results 121 to 130 of about 368,060 (192)
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform. [PDF]
HemasphereMosquera Orgueira A, Gonzalez Perez MS, D'Agostino M, Cairns DA, Larocca A, Palacios JJL, Wester R, Bertsch U, Waage A, Zamagni E, Pérez Míguez C, Rojas Martínez JA, Mai EK, Crucitti D, Salwender H, Dall'Olio D, Castellani G, Piñeiro Fiel M, Bringhen S, Zweegman S, Cavo M, Iqbal S, Hernandez Rivas JM, Bruno B, Cook G, Kaiser MF, Goldschmidt H, Van De Donk NWCJ, Jackson G, San-Miguel JF, Boccadoro M, Mateos MV, Sonneveld P. +32 moreeuropepmc +1 more sourceOutcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium. [PDF]
Blood AdvWang JS, Ellsworth BL, Melody M, Epperla N, Stephens D, Romancik J, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Matasar M, Herr MM, Davis J, Jesme C, Pelcovits AR, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover N, Karmali R. +29 moreeuropepmc +1 more sourceEUFOREA summit in Brussels 2025: inspiring the future of allergy and respiratory care. [PDF]
Front AllergyLau S, Backer V, Scadding GK, Barnes PJ, Bernal Sprekelsen M, Bertels X, Blaiss M, Borzova E, Brüggen MC, Cardell LO, Conti DM, Cornet M, De Corso E, Djukanovic R, Fokkens WJ, Fox AT, Gaga M, Gevaert P, Gibson P, Gray CL, Heaney LG, Heffler E, Hoffmann HJ, Hopkins C, Jackson D, Jesenak M, Johansen P, Khaleva E, Lee S, Mäkelä MJ, Melén E, Mullol J, Nieto A, Pavord I, Peters A, Price D, Quirce S, Ryan D, Schneider S, Senior B, Shire CME, Smith P, Teeling T, Virchow JC, Lund V, Wahn U, Hellings PW. +46 moreeuropepmc +1 more sourceInvestigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design. [PDF]
JACC AdvPlutzky J, Taub PR, Bhatt DL, Al Dhaybi O, Aroda VR, Basile JN, Bloch MJ, Budoff M, Busch RS, Buse JB, Cheung D, Christofides EA, DeFronzo RA, Galindo RJ, Handelsman Y, Laffin L, Parker JC, Rader F, Rosenstock J, Sloan LA, Tudor IC, Einhorn D. +21 moreeuropepmc +1 more sourceCell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma. [PDF]
Clin Cancer ResCliff ERS, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, Gould P, Cherng HJ, Houshyar S, Wallace DS, Lynch RC, Kallam A, Mei MG, Merryman RW, Fleyshman M, Rhodes JM, Kidwell A, Fenske TS, Malakhov N, Mulvey E, Watkins MP, Alhaj Moustafa M, Hilal T, Nowakowski GS, Wang Y, Torka P, Russler-Germain DA. +31 moreeuropepmc +1 more sourceNilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint. [PDF]
LeukemiaCastagnetti F, Breccia M, Abruzzese E, Bassan R, Binotto G, Bonifacio M, Caocci G, Capodanno I, Cavazzini F, Cimino G, Fazi P, Gozzini A, Iurlo A, Janssen JJWM, Lunghi M, Marasca R, Martino B, Messina M, Muriano F, Paoloni F, Piciocchi A, Rosti G, Russo Rossi A, Saglio G, Sica S, Soverini S, Tafuri A, Vallisa D, Westerweel PE, Pane F. +29 moreeuropepmc +1 more sourceEnabling Canadian Physician Wellness in the Age of Digital Innovation: What Do We Need to Succeed? [PDF]
Appl Clin InformTajirian T, Lo B, Tasca A, Poynter B, Zai G, Strudwick G, Chandrasena C, Jessa K, Shin P, Maggi J, Haider U, Pinfold A, Miller AP, Chisholm A, Lake D, Jankowicz D, Sockalingam S. +16 moreeuropepmc +1 more source
